NCT02465216View on ClinicalTrials.gov

Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Pulmonary Tuberculosis
Interventions
OTHER

Placebo

Placebo

BIOLOGICAL

ID93 + GLA-SE

ID93 + GLA-SE

Trial Locations (3)

6850

South African Tuberculosis Vaccine Initiative (SATVI), Worcester

7530

TASK Applied Sciences, Cape Town

7750

Desmond Tutu HIV Centre (DTHC), Cape Town

All Listed Sponsors
collaborator

Wellcome Trust

OTHER

collaborator

South African Tuberculosis Vaccine Initiative

OTHER

lead

Access to Advanced Health Institute (AAHI)

OTHER

NCT02465216 - Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion | Biotech Hunter | Biotech Hunter